Ignite Creation Date:
2025-12-24 @ 10:34 PM
Ignite Modification Date:
2026-02-23 @ 6:25 AM
Study NCT ID:
NCT03903835
Status:
RECRUITING
Last Update Posted:
2025-04-09
First Post:
2019-03-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C540278', 'term': 'enzalutamide'}, {'id': 'C089740', 'term': 'abiraterone'}, {'id': 'D000069501', 'term': 'Abiraterone Acetate'}, {'id': 'D016190', 'term': 'Carboplatin'}, {'id': 'C552428', 'term': 'cabazitaxel'}, {'id': 'D012996', 'term': 'Solutions'}, {'id': 'D007267', 'term': 'Injections'}, {'id': 'C581106', 'term': 'radium Ra 223 dichloride'}, {'id': 'C545685', 'term': 'niraparib'}, {'id': 'D011241', 'term': 'Prednisone'}, {'id': 'C575618', 'term': 'capivasertib'}, {'id': 'D000077143', 'term': 'Docetaxel'}, {'id': 'C572045', 'term': 'apalutamide'}, {'id': 'C000607739', 'term': 'darolutamide'}], 'ancestors': [{'id': 'D000736', 'term': 'Androstenes'}, {'id': 'D000731', 'term': 'Androstanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}, {'id': 'D004333', 'term': 'Drug Administration Routes'}, {'id': 'D004358', 'term': 'Drug Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D011244', 'term': 'Pregnadienediols'}, {'id': 'D011245', 'term': 'Pregnadienes'}, {'id': 'D011278', 'term': 'Pregnanes'}, {'id': 'D043823', 'term': 'Taxoids'}, {'id': 'D043822', 'term': 'Cyclodecanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D004224', 'term': 'Diterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'ProBio will use outcome-adaptive randomization, adapting the randomization based on the observed PFS within biomarker signatures. Treatments will initially be assigned to patients based on the biomarker signatures for which that treatment is most likely to be effective. The trial will be analysed within a Bayesian framework, which allows for calculations of the probability for each treatment that is superior to standard of care within a given signature. Each experimental arm will be evaluated for efficacy relative to the control arm with the same biomarker signatures.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 750}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2019-02-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-04-07', 'studyFirstSubmitDate': '2019-03-29', 'studyFirstSubmitQcDate': '2019-04-02', 'lastUpdatePostDateStruct': {'date': '2025-04-09', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-04-04', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression free survival (PFS) in mCRPC', 'timeFrame': 'Until progressive disease or 60 months from start of treatment, whatever occurs first.', 'description': 'Progression will be evaluated by the established international standards of the Prostate Cancer Working Group version 3 (PCWG3) and for soft tissue metastases (e.g. lung, liver and lymph nodes) according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1).'}, {'measure': 'Progression free survival (PFS) in mHSPC', 'timeFrame': 'From date of treatment start until the date of first documentation of progression, assessed up to 60 months', 'description': 'Time to development of castration-resistance, as defined by EAU guidelines (biochemical progression or radiologic progression)'}], 'secondaryOutcomes': [{'measure': 'Treatment response rate in mCRPC', 'timeFrame': '4 months after treatment start', 'description': 'Treatment response is evaluated according to PCWG3 and RECIST 1.1'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'From enrolment to completion of study (60 months)', 'description': 'OS is defined as time to death from any cause (overall and prostate cancer specific)'}, {'measure': 'Patient Reported Outcome Measures (PROM)', 'timeFrame': 'From enrolment to completion of study (60 months)', 'description': 'QoL will be assessed using the EORTC QLQ-C30 instrument'}, {'measure': 'Cost-effectiveness', 'timeFrame': 'From enrolment to completion of study (60 months)', 'description': 'Cost effectiveness will be assessed by using the EQ-5D-5L instrument to estimate health utilities. Treatment costs will be based on drug costs and reimbursement data.'}, {'measure': 'Number of Participants With Adverse Events as a Measure of Safety and Tolerability', 'timeFrame': 'From enrolment to completion of study (60 months)', 'description': 'Common Terminology Criteria for Adverse Events (CTCAE) developed and maintained by the US National Cancer Institute will be used to record adverse events'}, {'measure': 'Treatment response rate in mHSPC', 'timeFrame': '6 months after treatment start', 'description': 'Response rates at 6 months on therapy will be evaluated by the established standards of EAU Guidelines'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['mCRPC', 'mHSPC', 'cfDNA', 'Genomics', 'Liquid Biopsy'], 'conditions': ['Metastatic Castration-resistant Prostate Cancer (mCRPC)', 'Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)']}, 'referencesModule': {'references': [{'pmid': '40263079', 'type': 'DERIVED', 'citation': "Crippa A, Laere B, Discacciati A, Larsson B, Persson M, Johansson S, D'hondt S, Hjalm-Eriksson M, Pettersson L, Enblad G, Ullen A, Lumen N, Karlsson CT, Sandzen J, Janes E, Ghysel C, Olsson M, Sautois B, Schatteman P, Roock W, Bruwaene SV, Verbiene I, Darras J, Everaert E, Maeseneer D, Anden M, Strijbos M, Luyten D, Mortezavi A, Oldenburg J, Ost P, Lindberg J, Gronberg H, Eklund M; ProBio Investigators. Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial. Eur Urol Oncol. 2025 Apr 21:S2588-9311(25)00037-9. doi: 10.1016/j.euo.2025.02.002. Online ahead of print."}, {'pmid': '39164518', 'type': 'DERIVED', 'citation': "De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, D'hondt S, Bergstrom R, Chellappa V, Mayrhofer M, Banijamali M, Kotsalaynen A, Schelstraete C, Vanwelkenhuyzen JP, Hjalm-Eriksson M, Pettersson L, Ullen A, Lumen N, Enblad G, Thellenberg Karlsson C, Janes E, Sandzen J, Schatteman P, Nyre Vigmostad M, Olsson M, Ghysel C, Sautois B, De Roock W, Van Bruwaene S, Anden M, Verbiene I, De Maeseneer D, Everaert E, Darras J, Aksnessether BY, Luyten D, Strijbos M, Mortezavi A, Oldenburg J, Ost P, Eklund M, Gronberg H, Lindberg J. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. Nat Med. 2024 Nov;30(11):3291-3302. doi: 10.1038/s41591-024-03204-2. Epub 2024 Aug 20."}, {'pmid': '35317973', 'type': 'DERIVED', 'citation': 'De Laere B, Crippa A, Discacciati A, Larsson B, Oldenburg J, Mortezavi A, Ost P, Eklund M, Lindberg J, Gronberg H; ProBio Investigators. Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer. Eur Urol Focus. 2022 Nov;8(6):1617-1621. doi: 10.1016/j.euf.2022.03.005. Epub 2022 Mar 19.'}, {'pmid': '32586393', 'type': 'DERIVED', 'citation': 'Crippa A, De Laere B, Discacciati A, Larsson B, Connor JT, Gabriel EE, Thellenberg C, Janes E, Enblad G, Ullen A, Hjalm-Eriksson M, Oldenburg J, Ost P, Lindberg J, Eklund M, Gronberg H. The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials. 2020 Jun 26;21(1):579. doi: 10.1186/s13063-020-04515-8.'}]}, 'descriptionModule': {'briefSummary': 'ProBio is an international, outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven platform trial in patients with metastatic prostate cancer. Patients will be randomized to control or experimental treatment arms. Patients in the control arm will receive standard of care following national guidelines. Patients in the experimental arm will be randomized to treatments based on a biomarker signature inferred from diagnostic tissue or liquid biopsy profiling. The predefined biomarker signatures are tumor properties or mutations in genes/pathways with previously demonstrated clinical validity (e.g. prognostic value or association with treatment response). The biomarker signatures are identified using a hybridisation capture gene panel specifically designed for prostate cancer.', 'detailedDescription': "ProBio is an outcome-adaptive, multi-arm, open-label, multiple assignment randomised biomarker driven platform trial in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.\n\nPatients will be randomised to control or experimental treatment class arms. Patients in the control arm will receive standard of care following national guidelines and will remain within the control arm throughout the course of the trial. Patients in the experimental arm will be randomised to a treatment class (consisting of one or multiple drugs) based on a biomarker signature. The biomarker signatures are defined as tumour properties or mutations in certain genes/pathways identified in the scientific literature as important in prostate cancer treatment response. The biomarker signatures are identified using a gene panel specifically designed for advanced prostate cancer.\n\nAlterations in the following genes/pathways or combinations thereof constitute the biomarker signatures:\n\n* Androgen receptor\n* DNA-repair deficiency\n* TP53\n* TMPRSS2-ERG gene fusion\n* PI3K pathway alterations\n\nPatients in the experimental arm can be randomized to the following treatments classes:\n\nfor mHSPC\n\n* AR signalling inhibitors (Abiraterone acetate, Enzalutamide, Apalutamide)\n* Taxane-based chemotherapy in combination with ARSi (Docetaxel plus Abiraterone acetate, or Darolutamide)\n* PolyADP Ribose Polymerase Inhibitors (Niraparib plus Abiraterone Acetate)\n\nfor mCRPC\n\n* AR signalling inhibitors (Enzalutamide, Abiraterone acetate)\n* Poly ADP Ribose Polymerase Inhibitors (Niraparib plus Abiraterone acetate)\n* Selective AKT Inhibitor (Capivasertib plus Docetaxel)\n\nProBio will use outcome-adaptive randomization, adapting the randomization based on the observed progression free survival (PFS) within biomarker signatures. Treatments will initially be assigned to patients based on the biomarker signatures for which that treatment is most likely to be effective. The trial will be analyzed within a Bayesian framework, which allows for calculations of the probability for each treatment that it is superior to standard of care within a given signature. Each experimental arm will be evaluated for efficacy relative to the control arm with the same biomarker signatures.\n\nParticipants and treating physicians will be blinded to ctDNA profile of each patient. The biomarker signatures will thus not influence treatment choice among controls (reflecting today's standard of care).\n\nFurther, ProBio will use the sequential multiple assignments trial (SMART) concept, where each patient who progresses within the trial will re-enter the trial and be re-assigned to another treatment based on the patient's current ctDNA profile. Patients will be withdrawn after in total maximal three randomized consecutive treatments after inclusion into the study.\n\nThe randomization probabilities within the experimental arm are defined in proportion to the probability that each treatment is superior to standard of care within a given biomarker signature, and therefore change as data accumulates in the trial and knowledge accumulates for what biomarker signatures and specific treatments that are more probable to be effective.\n\nTrial results will be evaluated regularly by an independent data and safety monitoring board (DSMB). The DSMB will evaluate treatment-signature combinations with respect to:\n\n* Graduation for superiority: A treatment-biomarker signature combination will be graduated from the trial if it has a Bayesian predictive probability of success in a future confirmatory phase III trial exceeding a pre-specified threshold (85%).\n* Termination for futility: Treatment-biomarker signature combinations will be dropped from the trial for futility when success probabilities drop sufficiently low (less than 10% using a minimum of 20 patients assigned to the specific treatment-biomarker signature combination).\n* Alternatively, if the maximum sample size of 300 and 150 patients (for mHSPC and mCRPC, respectively) assigned to a treatment biomarker signature is reached without graduation for superiority, assignments to that combination will end.\n\nProBio is a platform study. This means that new treatments and biomarker signatures can be added to the experimental arm in the future. This will be done after protocol amendments."}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Man with histologically confirmed prostate adenocarcinoma, initiating systemic therapy for metastatic disease, encompassing newly diagnosed (i.e. de novo) hormone sensitive prostate cancer (mHSPC) or first-line castration resistant prostate cancer (mCRPC)\n* Distant metastatic disease documented by positive bone scan or metastatic lesions on CT or MRI\n* Adequate health as assessed by the investigator to receive all available treatments in the trial\n* ECOG/WHO (Eastern Cooperative Oncology Group/ World Health Organization) performance score 0-2\n* Adequate organ and bone marrow function\n* Albumin greater than or equal to 28 g/L\n* Able to understand the patient information and sign written informed consent\n\nExclusion Criteria:\n\n* Other malignancies within 5 years except non-melanoma skin cancer\n* Within 6 months of randomization: myocardial infarction, unstable angina, angioplasty, bypass surgery, stroke, TIA (transient ischemic attack), or congestive heart failure NYHA (New York Heart Association) class III or IV\n* Uncontrolled hypertension\n* Uncontrolled hypotension\n* Received systemic therapy (with the exception of standard ADT) prior to study inclusion, for the CRPC indication\n* Any severe acute or chronic medical condition that places the patient at increased risk of serious toxicity or interferes with the interpretation of study results\n* Unable to comply with study procedures\n* Current participation in another clinical trial that will be in conflict with the present study, administration of an investigational therapeutic or invasive surgical procedure within 28 days prior to study enrolment\n* Patients who are unlikely to comply with the protocol\n* Any condition or situation which, in the opinion of the investigator, would put the subject at risk, may confound study results, or interfere with the subjects participation in this study.\n* Any medical condition that would make use of the study treatments contraindicated, according to the SmPC, e.g. significant heart or liver disease.'}, 'identificationModule': {'nctId': 'NCT03903835', 'acronym': 'ProBio', 'briefTitle': 'ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Karolinska Institutet'}, 'officialTitle': 'ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer', 'orgStudyIdInfo': {'id': 'EudraCT No 2018-002350-78'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Control: Standard Care', 'description': 'Randomization between assignment to the control arm or the biomarker driven arm will be stratified on biomarker signatures, previous treatment, and fraction of ctDNA and will therefore occur after the results from the ctDNA profiling is obtained. Patients in the control arm will receive standard of care following national guidelines.', 'interventionNames': ['Drug: Enzalutamide Oral Capsule', 'Drug: Abiraterone Oral Tablet', 'Drug: Cabazitaxel 60 mg Solution for Injection', 'Drug: Docetaxel Injectable Solution', 'Drug: Radium Chloride Ra-223', 'Drug: Apalutamide']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment 1 in mHSPC: AR signalling inhibitors (ARSi)', 'description': 'Assignments to therapy in the biomarker driven arms will be done on the basis of the biomarker signature using the current information about the efficacy of the various regimens for that signature. Information from previous studies may be incorporated in the randomization at study onset if such reliable data exists. Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment with ARSi.', 'interventionNames': ['Drug: Enzalutamide Oral Capsule', 'Drug: Abiraterone Oral Tablet', 'Drug: Apalutamide']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment 2 in mHSPC: taxane-based chemotherapy in combination with ARSi', 'description': 'Patients with TP53 mutations and TMPRSS2-ERG gene fusions will have an increased chance of being randomised to treatment with chemotherapy plus an ARSi.', 'interventionNames': ['Drug: Abiraterone Oral Tablet', 'Drug: Docetaxel Injectable Solution', 'Drug: Darolutamide']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment 3 in mHSPC: Poly ADP Ribose Polymerase (PARP) inhibitor', 'description': 'DNA-repair deficient patients will have an increased chance of receiving PARP inhibitors at study onset.', 'interventionNames': ['Drug: Niraparib plus Abiraterone acetate plus Prednisone']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment 1 in mCRPC: AR signalling inhibitors (ARSi)', 'description': 'Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment with ARSi.', 'interventionNames': ['Drug: Enzalutamide Oral Capsule', 'Drug: Abiraterone Oral Tablet']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment 2 in mCRPC: Poly ADP Ribose Polymerase (PARP) inhibitor', 'description': 'DNA-repair deficient patients will have an increased chance of receiving PARP inhibitors at study onset.', 'interventionNames': ['Drug: Niraparib plus Abiraterone acetate plus Prednisone']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment 3 in mCRPC: selective AKT Inhibitor', 'description': 'Patients with alterations in the PI3K pathway will have an increased chance of receiving the combination treatment with Capivasertib plus Docetaxel.', 'interventionNames': ['Drug: Capivasertib plus Docetaxel']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment 4 in mCRPC: Carboplatin', 'description': 'Only patients with DNA-repair deficiency will be treated with Carboplatin as second line treatment in the castration-resistant phase of ProBio.', 'interventionNames': ['Drug: Carboplatin']}], 'interventions': [{'name': 'Enzalutamide Oral Capsule', 'type': 'DRUG', 'otherNames': ['Xtandi'], 'description': 'Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).', 'armGroupLabels': ['Control: Standard Care', 'Treatment 1 in mCRPC: AR signalling inhibitors (ARSi)', 'Treatment 1 in mHSPC: AR signalling inhibitors (ARSi)']}, {'name': 'Abiraterone Oral Tablet', 'type': 'DRUG', 'otherNames': ['Zytiga'], 'description': 'Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.', 'armGroupLabels': ['Control: Standard Care', 'Treatment 1 in mCRPC: AR signalling inhibitors (ARSi)', 'Treatment 1 in mHSPC: AR signalling inhibitors (ARSi)', 'Treatment 2 in mHSPC: taxane-based chemotherapy in combination with ARSi']}, {'name': 'Carboplatin', 'type': 'DRUG', 'description': 'Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \\[GFR ml/min + 25\\].', 'armGroupLabels': ['Treatment 4 in mCRPC: Carboplatin']}, {'name': 'Cabazitaxel 60 mg Solution for Injection', 'type': 'DRUG', 'description': 'Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.', 'armGroupLabels': ['Control: Standard Care']}, {'name': 'Docetaxel Injectable Solution', 'type': 'DRUG', 'description': 'Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.', 'armGroupLabels': ['Control: Standard Care', 'Treatment 2 in mHSPC: taxane-based chemotherapy in combination with ARSi']}, {'name': 'Radium Chloride Ra-223', 'type': 'DRUG', 'otherNames': ['Xofigo'], 'description': 'Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.', 'armGroupLabels': ['Control: Standard Care']}, {'name': 'Niraparib plus Abiraterone acetate plus Prednisone', 'type': 'DRUG', 'otherNames': ['Akeega'], 'description': "Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.", 'armGroupLabels': ['Treatment 2 in mCRPC: Poly ADP Ribose Polymerase (PARP) inhibitor', 'Treatment 3 in mHSPC: Poly ADP Ribose Polymerase (PARP) inhibitor']}, {'name': 'Capivasertib plus Docetaxel', 'type': 'DRUG', 'description': 'Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.', 'armGroupLabels': ['Treatment 3 in mCRPC: selective AKT Inhibitor']}, {'name': 'Apalutamide', 'type': 'DRUG', 'otherNames': ['Erleada'], 'description': 'Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).', 'armGroupLabels': ['Control: Standard Care', 'Treatment 1 in mHSPC: AR signalling inhibitors (ARSi)']}, {'name': 'Darolutamide', 'type': 'DRUG', 'otherNames': ['Nubeqa'], 'description': 'Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).', 'armGroupLabels': ['Treatment 2 in mHSPC: taxane-based chemotherapy in combination with ARSi']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Aalst', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Peter Schatterman, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'OLV Ziekenhuis Aalst', 'geoPoint': {'lat': 50.93604, 'lon': 4.0355}}, {'city': 'Antwerp', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Michiel Strijbos, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'GZA Sint-Augustinus', 'geoPoint': {'lat': 51.22047, 'lon': 4.40026}}, {'zip': 'B-8000', 'city': 'Bruges', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Christophe Ghysel, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AZ Sint-Jan AV', 'geoPoint': {'lat': 51.20892, 'lon': 3.22424}}, {'city': 'Bruges', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Daan De Maeseneer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AZ Sint-Lucas', 'geoPoint': {'lat': 51.20892, 'lon': 3.22424}}, {'city': 'Genk', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Wendy De Roock, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Ziekenhuis Oost-Limburg', 'geoPoint': {'lat': 50.965, 'lon': 5.50082}}, {'zip': 'B-9000', 'city': 'Ghent', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Piet Ost, Prof. dr.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University Hospital Ghent', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'city': 'Ghent', 'status': 'NOT_YET_RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Caroline Verbaeys, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AZ Jan Palfijn Ziekenhuis', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'city': 'Hasselt', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Daisy Luyten, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Jessa ziekenhuis', 'geoPoint': {'lat': 50.93106, 'lon': 5.33781}}, {'city': 'Kortrijk', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Siska Van Bruwaene', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AZ Groeninge', 'geoPoint': {'lat': 50.82803, 'lon': 3.26487}}, {'city': 'Liège', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Brieuc Sautois, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University Hospital Luik', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'city': 'Ostend', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Jochen Darras, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AZ Damiaan', 'geoPoint': {'lat': 51.21551, 'lon': 2.927}}, {'city': 'Sint-Niklaas', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Bram De Laere, PhD', 'role': 'CONTACT', 'email': 'bramdlae.DeLaere@ugent.be'}, {'name': 'Els Everaert, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'VITAZ', 'geoPoint': {'lat': 51.16509, 'lon': 4.1437}}, {'city': 'Ålesund', 'status': 'NOT_YET_RECRUITING', 'country': 'Norway', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Bjorg Y Aksnessaether, MD PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Ålesund Sjukehus', 'geoPoint': {'lat': 62.47225, 'lon': 6.15492}}, {'city': 'Kristiansand', 'status': 'RECRUITING', 'country': 'Norway', 'contacts': [{'name': 'Maria Persson, RN', 'role': 'CONTACT', 'email': 'maria.persson.3@ki.se'}, {'name': 'Christoph Müller, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Kreftsenter Kristiansand', 'geoPoint': {'lat': 58.14671, 'lon': 7.9956}}, {'city': 'Lørenskog', 'status': 'RECRUITING', 'country': 'Norway', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT'}, {'name': 'Jan Oldenburg, Prof. dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Akershus Universitetssykehus'}, {'city': 'Stavanger', 'status': 'RECRUITING', 'country': 'Norway', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT'}, {'name': 'Maria N Vigmostad, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Stavanger Universitetssjukehus', 'geoPoint': {'lat': 58.97005, 'lon': 5.73332}}, {'city': 'Tromsø', 'status': 'NOT_YET_RECRUITING', 'country': 'Norway', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Hege S Haugnes, Prof, dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universitetssykehuset Nord-Norge Tromsö', 'geoPoint': {'lat': 69.6489, 'lon': 18.95508}}, {'zip': '79182', 'city': 'Falun', 'state': 'Region Dalarna', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT'}, {'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Ingrida Verbiéne, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Falu lasarett', 'geoPoint': {'lat': 60.60357, 'lon': 15.62597}}, {'city': 'Borås', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Susanne Johansson, B.Sc.', 'role': 'CONTACT', 'email': 'susanne.johansson@ki.se'}, {'name': 'Christine Jaredsson, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Södra Alvsborgs sjukhus', 'geoPoint': {'lat': 57.72101, 'lon': 12.9401}}, {'zip': '551 11', 'city': 'Jönköping', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Linn Pettersson, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Länssjukhuset Ryhov - Onkologiska kliniken', 'geoPoint': {'lat': 57.78145, 'lon': 14.15618}}, {'zip': '392 44', 'city': 'Kalmar', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Mats Andén, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Länssjukhuset', 'geoPoint': {'lat': 56.66157, 'lon': 16.36163}}, {'zip': '651 85', 'city': 'Karlstad', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Johan Sandzen, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centralsjukhuset Region Värmland', 'geoPoint': {'lat': 59.3793, 'lon': 13.50357}}, {'city': 'Örebro', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Susanne Johansson, B.Sc.', 'role': 'CONTACT', 'email': 'susanne.johansson@ki.se'}, {'name': 'Jenny Kahlmeter Brandell, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universitetssjukhuset Örebro', 'geoPoint': {'lat': 59.27412, 'lon': 15.2066}}, {'zip': '17176', 'city': 'Stockholm', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Anders Ullén, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Karolinska University Hospital', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'city': 'Stockholm', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Henrik Grönberg, Professor', 'role': 'CONTACT', 'email': 'henrik.gronberg@capiostgoran.se'}, {'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Marie Hjälm Eriksson, MD PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Capio St.Görans Hospital', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'zip': '851 86', 'city': 'Sundsvall', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Elin Jänes, MD PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Länssjukhuset Sundsvall Härnösand', 'geoPoint': {'lat': 62.39129, 'lon': 17.3063}}, {'zip': '90185', 'city': 'Umeå', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Camilla Thellenberg Karlsson, MD PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Norrlands Universitetssjukhus', 'geoPoint': {'lat': 63.82842, 'lon': 20.25972}}, {'zip': '75185', 'city': 'Uppsala', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Gunilla Enblad, Professor', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Akademiska sjukhuset', 'geoPoint': {'lat': 59.85882, 'lon': 17.63889}}, {'city': 'Varberg', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Susanne Johansson, B.Sc.', 'role': 'CONTACT', 'email': 'susanne.johansson@ki.se'}, {'name': 'Ingela Franck Lissbrant, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hallands sjukhus Varberg', 'geoPoint': {'lat': 57.10557, 'lon': 12.25078}}, {'zip': '351 85', 'city': 'Vaxjo', 'status': 'RECRUITING', 'country': 'Sweden', 'contacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se'}, {'name': 'Martha Olsson, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centrallasarettet Onkologkliniken', 'geoPoint': {'lat': 56.87767, 'lon': 14.80906}}, {'city': 'Basel', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Maria Persson, RN', 'role': 'CONTACT', 'email': 'maria.persson.3@ki.se'}, {'name': 'Arnoud Templeton, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'St. Claraspital', 'geoPoint': {'lat': 47.55839, 'lon': 7.57327}}, {'city': 'Basel', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Maria Persson, RN', 'role': 'CONTACT', 'email': 'maria.persson.3@ki.se'}, {'name': 'Ashkan Mortezavi, MD PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universitätsspital Basel', 'geoPoint': {'lat': 47.55839, 'lon': 7.57327}}], 'centralContacts': [{'name': 'Berit Larsson, MSc', 'role': 'CONTACT', 'email': 'berit.larsson@ki.se', 'phone': '+46 8 52482576'}, {'name': 'Henrik Grönberg, Professor', 'role': 'CONTACT', 'email': 'Henrik.gronberg@ki.se', 'phone': '+46 70 3411356'}], 'overallOfficials': [{'name': 'Henrik Grönberg, Professor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Karolinska Institutet'}, {'name': 'Martin Eklund, Professor', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Karolinska Institutet'}, {'name': 'Johan Lindberg, PhD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Karolinska Institutet'}, {'name': 'Piet Ost, Professor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Hospital Ghent, Belgium'}, {'name': 'Jan Oldenburg, Professor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Hospital, Akershus'}, {'name': 'Ashkan Mortezavi, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Hospital, Basel, Switzerland'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Karolinska Institutet', 'class': 'OTHER'}, 'collaborators': [{'name': 'The Swedish Research Council', 'class': 'OTHER_GOV'}, {'name': 'Kom Op Tegen Kanker', 'class': 'OTHER'}, {'name': 'Janssen Pharmaceutica N.V., Belgium', 'class': 'INDUSTRY'}, {'name': 'AstraZeneca', 'class': 'INDUSTRY'}, {'name': 'Cancerfonden', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor of Cancer Epidemiology', 'investigatorFullName': 'Henrik Grönberg', 'investigatorAffiliation': 'Karolinska Institutet'}}}}